FTSE MIB
34.490,71 +23,04 (+0,07%) Dow Jones
39.069,59 +4,33 (+0,01%) Nasdaq
16.920,79 +184,76 (+1,10%) Nikkei 225
38.646,11 -457,11 (-1,17%) Petrolio
77,80 +0,93 (+1,21%) Bitcoin EUR
63.977,17 +1.955,56 (+3,15%)
Qiagen N.V. (QIAN.MX)
| Chiusura precedente | 757,36 |
| Aperto | 0,00 |
| Denaro | 0,00 x N/D |
| Domanda | 0,00 x N/D |
| Min-Max giorno | 784,36 - 784,36 |
| Intervallo di 52 settimane | 721,91 - 898,11 |
| Volume | |
| Media Volume | 536 |
| Capitalizzazione | N/D |
| Beta (mensile su 5 anni) | 0,42 |
| Rapporto PE (ttm) | 16,53 |
| EPS (ttm) | 47,46 |
| Prossima data utili | 06 ago 2024 - 12 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireQIAGEN N.V. to release results for Q3 2023 and hold webcast
Venlo, the Netherlands, Oct. 09, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter 2023. Press release date / time: Monday, October 30, shortly after 21:05 Frankfurt time / 20:05 London time / 16:05 New York time. (For Europe: Due to the U.S. time switch, our Press release will be published one hour earlier than usual.) Conference call date / time: Tuesday, October 31, at 14:00 Frankfurt time / 13:00 Lon
GlobeNewswireQIAGEN launches QuantiFERON-EBV RUO assay, facilitating research of cell-mediated immune response to Epstein-Barr virus
QuantiFERON-EBV RUO to help researchers understand Epstein-Barr virus (EBV) infections and related malignancies, offering a dynamic view of the host immune response // Advancing research in oncology and autoimmune diseases through measurement of T-cell responses to EBV, providing valuable insights into the virus’ role in these conditions // Further expanding portfolio of QuantiFERON cell-mediated immune response tests beyond tuberculosisVenlo, the Netherlands, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Q
GlobeNewswireQIAGEN extends AI capabilities of its NGS interpretation software QCI Interpret to enable clinical exome completeness
AI-driven literature extraction for thousands of rare disease genes fortifies and extends QIAGEN’s proprietary, human-certified content, providing complete bibliographic coverage of the clinical exome // Enhanced AI-trained phenotype driven ranking of pathogenic variants improves accuracy and efficiency of prioritizing candidate variants // New features reduce time needed for prioritization, assessment and interpretation of clinically relevant variants and facilitate access to trusted evidence f
